01—Abstract
Summary
Summary of the 8-K filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Biogen reported third quarter 2025 results on October 30, 2025, with total revenue of $2.53 billiona, up 3% year-over-year (2% at constant currency), and GAAP diluted EPS of $3.17, up 19%.
Non-GAAP diluted EPS was $4.81b, up 18%. Growth was led by launch products: LEQEMBI global in-market sales were approximately $121 million (up 82%), SKYCLARYS global revenue was about $133 million (up 30%), and ZURZUVAE revenue was about $55 million. The MS franchise was flat at constant currency, supported by a favorable gross-to-net adjustment and VUMERITY strength, while TECFIDERA faced continued generic erosion in Europe.
Revenue from contract manufacturing and other sources fell 35%, and Biogen's reported Q3 GAAP cost of sales included a $104 millionc charge tied to a TYSABRI royalty judgment (Genentech claim). The most important change for investors is the revised 2025 Non-GAAP EPS guidance of $14.50 to $15.00, down from $15.50 to $16.00 in July. Biogen raised its underlying outlook by about $0.25, but expects roughly a $1.25 per-share hit in Q4 from acquired IPR&D tied to business development deals expected to close that quarter, including the Vanqua Bio C5aR1 license ($70 million upfront) and the pending Alcyone Therapeutics acquisition ($85 million upfront plus milestones).
Full-year 2025 total revenue guidance was nudged up to approximately flat to +1%d at constant currency, though management flagged increased ex-U.S. MS competition in Q4. Pipeline and balance sheet news was also notable. Management highlighted the FDA resubmission of high-dose SPINRAZA with a PDUFA date of April 3, 2026, full enrollment of both litifilimab Phase 3 lupus studies with data now expected in H2 2026, and a rolling FDA submission for LEQEMBI IQLIK treatment initiation.
Biogen ended the quarter with about $4.0 billion in cash and $6.3 billion in total debt, leaving net debt of roughly $2.3 billion. Operating cash flow was about $1.3 billion and free cash flow about $1.2 billion in the quarter.
02—Key points
Key Highlights
- Q3 2025 total revenue of $2.535B grew 3% YoY (2% at constant currency); GAAP EPS $3.17 (+19%) and Non-GAAP EPS $4.81 (+18%).
- Full-year 2025 Non-GAAP EPS guidance lowered to $14.50–$15.00 from $15.50–$16.00, driven by an expected ~$1.25 Q4 IPR&D charge, partly offset by a ~$0.25 improvement in underlying business outlook.
- Full-year 2025 total revenue guidance raised to approximately flat to +1% at constant currency, up from approximately flat.
- Launch products grew strongly: LEQEMBI global sales ~$121M (+82%), SKYCLARYS ~$133M (+30%), and ZURZUVAE ~$55M; Alzheimer's collaboration revenue more than doubled to $43M.
- MS franchise was flat YoY (-0.4% at constant currency) with VUMERITY strength offset by TECFIDERA generic erosion in Europe; management expects more ex-U.S. MS competitive pressure in Q4.
- Q3 GAAP cost of sales included a $104.3M charge related to a judgment on Genentech's claim for past TYSABRI royalties and interest; contract manufacturing revenue fell 35%.
- Pipeline progress: high-dose SPINRAZA resubmitted (PDUFA April 3, 2026), both litifilimab SLE Phase 3 studies fully enrolled with readouts accelerated to H2 2026, and an IRAK4 degrader entered Phase 1.
03—Questions
Frequently Asked Questions
Why did Biogen lower its full-year 2025 EPS guidance if business performance improved?
The reduction is not from weaker operations. Biogen raised its underlying business outlook by about $0.25 per share, but expects roughly a $1.25 per-share impact in Q4 2025 from acquired in-process R&D expense tied to business development transactions expected to close that quarter, including the Vanqua Bio C5aR1 license ($70 million upfront) and the Alcyone Therapeutics acquisition ($85 million upfront plus milestones). The net result is a revised Non-GAAP EPS range of $14.50 to $15.00.
How is the core MS franchise performing, and what risks lie ahead?
The MS franchise grew 1% reported and was flat at constant currency in Q3 2025, helped by a favorable gross-to-net adjustment and timing of VUMERITY shipments. U.S. demand for VUMERITY is growing, but TECFIDERA continues to erode in Europe from generic competition. Management expects increased competitive pressure on ex-U.S. MS in Q4 2025, particularly for TECFIDERA in Europe, so investors should watch whether the franchise can keep stabilizing.
What drove the drop in gross margin and the large cost of sales charge?
GAAP cost of sales rose to 27% of revenue from 26%, mainly because of a pre-tax charge of about $104 million tied to a judgment on Genentech's claim for past TYSABRI royalties and interest. Non-GAAP cost of sales fell to 20% of revenue from 24%, largely due to a mix shift away from lower-margin contract manufacturing revenue, which declined 35% year over year. Management guided Q4 2025 manufacturing revenue to $10–20 million.
How strong is Biogen's balance sheet and cash generation after the recent deals?
As of September 30, 2025, Biogen had about $4.0 billion in cash and equivalents against about $6.3 billion in total debt, for net debt of roughly $2.3 billion. Q3 operating cash flow was about $1.3 billion and free cash flow about $1.2 billion. The pending Q4 acquisitions and licenses will add cash outflows, so net debt and cash deployment will be important to track in future filings.
04—Continue